

BRAND NAME	Ubrelvy®	Nurtec® ODT	Qulipta™
GENERIC NAME	ubrogepant	rimegepant	atogepant
MANUFACTURER	AbbVie	Biohaven Pharmaceuticals	AbbVie
INDICATION	Acute treatment of migraine	Acute treatment of migraine & preventive treatment of episodic migraine	Preventive treatment of episodic migraine
PRICE & SAVINGS PLAN	As low as \$0 for eligible commercially insured patients using savings program: www.ubrelvy.com/savings	As low as \$0 for eligible commercially insured patients with savings program: www.nurtec.com/savings	As low as \$0 for eligible commercially insured patients with savings program: www.qulipta.com/savings
DOSAGE	50 or 100 mg, as needed Max dose: 200 mg in 24 hours	Acute: 75 mg, as needed Max 75 mg in 24 hours Prevent: 75 mg every other day Max dose: 75 mg in 24 hours	10 mg, 30 mg, or 60 mg orally once daily Max dose: 60 mg in 24 hours
EFFICACY *See individual websites for complete study results	Measured at 2 hours post-dose Pain Relief: 60.7% at 50mg 61.4% at 100mg Pain Free: 19.2% at 50mg 21.2% at 100mg	Acute, measured at 2 hrs post-dose Pain Free: 21.2% at 75mg Pain Relief: 59.3% at 75mg Prevention: 30% reduction in weekly migraine days at Week 1	53% migraine day reduction in week 1 54% migraine day reduction across 12 weeks
HALF LIFE	5-7 hours	11 hours	11 hours
PRIMARY SIDE EFFECTS	nausea and sleepiness	nausea, stomach pain, indigestion	nausea, constipation, decreased appetite and fatigue